RELATIVITY-098 is a randomized Phase 3, double-blind study evaluating adjuvant immunotherapy with Opdualag, the fixed-dose combination of nivolumab and relatlimab, compared to Opdivo monotherapy ...
The company sates: “Bristol Myers (BMY) Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients with ...
after taking a final investment decision on the 12 mpta project in August 2019. The company said this was despite “substantial impacts including two hurricanes, the Covid-19 pandemic and major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback